-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Lineage Cell Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.84M, a 42.7% increase year-over-year.
- Lineage Cell Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$22.7M, a 9.12% increase year-over-year.
- Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$24.7M, a 9.83% decline from 2022.
- Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$22.5M, a 54.2% increase from 2021.
- Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$49.2M, a 86.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)